Targeted Therapy of Ewing's Sarcoma

Table 2

Small-molecule inhibitors of insulin-like growth factor 1 receptor (IGF1R).

Drug	Manufacturer	Current status	Reference
OSI-906	OSI Pharmaceuticals	In vivo and in vitro activity in EWS, some activity in chondrosarcoma	[32]
BMS-554417	Bristol-Myers Squibb	In vitro activity against EWS	[33]
XL-228	Exelixis	A multitargeted protein kinase inhibitor targeting IGF1R, FGFR1-3, the Aurora kinases, and the ABL, ALK, and SRC family kinases	[34]
INSM-18	Insmed and UCSF	Orally bioavailable small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF1R and human epidermal growth factor receptor (Her2/Neu).	[21]
GSK1904529A and GSK1838705A	GlaxoSmithKline	In vitro activity in EWS cell lines	[35, 36]

EWS: Ewing’s sarcoma; FGFR1-3: fibroblast growth factor receptor 1–3.